Nutriband 2026 Q3 Earnings Sharp Net Loss Widens by 184.2% Amid Revenue Decline

Nutriband (NTRB) reported its fiscal 2026 Q3 earnings on Dec 11, 2025, with results falling significantly short of expectations. The company’s revenue and net income both contracted sharply, reflecting ongoing operational challenges.

Nutriband’s total revenue for Q3 2026 dropped significantly to $346,058, a 46.4% decline from $645,796 in the same period last year. The Pocono Pharmaceuticals segment accounted for the entire revenue, reflecting a complete reliance on this division.

Nutriband’s losses deepened to $0.32 per share in 2026 Q3, a 166.7% wider loss compared to $0.12 per share in 2025 Q3. The company’s net loss widened to $-3.87 million, a 184.2% increase from $-1.36 million in 2025 Q3. This marks the seventh consecutive year of losses in the corresponding quarter, underscoring persistent financial headwinds. The company’s earnings per share and net loss both deteriorated sharply, underscoring ongoing financial challenges.

Nutriband’s stock price exhibited mixed short-term performance: climbing 4.63% during the latest trading day, edging down 1.78% during the most recent full trading week, and plummeting 16.75% month-to-date. The strategy of buying NTRB when earnings beat and selling after 30 days delivered moderate performance but underperformed the market. The strategy achieved a 7.76% return, trailing the benchmark by 49.59%. With a maximum drawdown of 0.00% and a Sharpe ratio of 0.01, the strategy indicated a low-risk profile but lacked significant growth potential.

**

**

Additional News

In the three weeks leading up to Dec 11, 2025, Nutriband announced key developments:

1. CEO Changes: Serguei Melnik assumed the role of interim CEO following the temporary departure of the previous leader to pursue a political nomination in Ireland.

2. FDA Meeting Success: The company confirmed a successful meeting with the U.S. FDA to discuss its Abuse Deterrent Fentanyl Patch, a critical step for regulatory approval.

3. Patent Filing: Nutriband filed a provisional patent application for its enhanced transdermal abuse-deterrent technology, signaling innovation in its pipeline.

These updates highlight strategic shifts in leadership and product development, though financial performance remains a pressing concern.

Article Polishing

• Transitions between sections have been refined for smoother readability.

• Punctuation and spacing irregularities were corrected.

• Original statistics and section structure (e.g., bold headings) were preserved.

• The

placeholder was inserted after a relevant paragraph.

• The

placeholder was appended to the specified paragraph, adhering to formatting rules.